Preliminary Evidence Suggests That a 12-Week Treatment with Tirzepatide Plus Low-Energy Ketogenic Therapy Is More Effective than Its Combination with a Low-Calorie Diet in Preserving Fat-Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients with Obesity

Nutrients, Journal Year: 2025, Volume and Issue: 17(7), P. 1216 - 1216

Published: March 30, 2025

Background: Tirzepatide (TZP), a unimolecular dual agonist targeting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, is promising weight loss agent in obesity. The preservation of metabolically active fat-free mass (FFM), muscle strength (MS), resting metabolic rate (RMR) essential for optimizing fat (FM) reduction. Although TZP typically combined with low-calorie diet (LCD), its impact on FFM uncertain, studies MS RMR are lacking. Evidence suggests that Low-Energy Ketogenic Therapy (LEKT) may reduce FM while preserving FFM, MS, RMR. Therefore, this study aimed to compare the effects an LEKT LCD, both TZP, body (BW), FM, patients Methods: We prospectively compared either LCD or 60 obesity (n = 30 per group) over 12 weeks. BW, were measured at baseline after Clinical parameters, assessment dietary compliance, side also evaluated. Results: At 12-week follow-up, groups showed significant BW reduction from (TZP+LEKT, p 0.0289; TZP+LCD, 0.0278), no intergroup difference (p 0.665). Similarly, decreased significantly cohorts < 0.001; 0.0185), TZP+LEKT group achieving greater 0.042). However, TZP+LCD exhibited declines 0.0284), 0.0341), 0.001), whereas we did not observe any changes 0.487), 0.691), 0.263) group. Intergroup direct comparisons confirmed experienced reductions 0.0388), 0.046), 0.019). Conclusions: Based findings these preliminary data, able support hypothesis seems be superior promoting

Language: Английский

Bio‐Nano Innovations Targeting the Neurovascular Complex for Epilepsy Treatment

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: April 30, 2025

Abstract Epilepsy is a prevalent chronic neurological disorder characterized by seizures resulting from an imbalance between excitatory and inhibitory neurons. While pharmacotherapy remains the standard treatment, traditional faces significant challenges, including poor brain penetration, high drug resistance rates, providing only symptomatic relief, rather than addressing underlying causes for comprehensive cure. Recently, neurovascular complex (NVC) has gained attention its critical role in development progression of epilepsy. Simultaneously, various innovative bio‐nanotechnology systems have emerged, specifically designed to enhance delivery across enable precise targeting within lesion. Herein, this review begins outlining core NVC involved epilepsy breaking it down into four key components: blood‐brain barrier (BBB), neurons, glial cells, microenvironment. The viability improve therapy analyzed. Next, systems, detailing their design principles, construction strategies, preclinical evaluations are highlighted. Finally, prospects next‐generation nanotechnologies challenges that must be overcome effective clinical translation discussed. Overall, aims guide more efficient bio‐nano therapies, ultimately enhancing treatment outcomes patients.

Language: Английский